Two novel compounds currently in development – bapineuzumab and solanezumab – for the treatment of Alzheimer’s disease expect to release phase III data in 2012. Those results may usher in a new era, or may add names to the list of high-profile setbacks in AD therapeutics such as tarenflurbil (Myriad), semagacestat (Lilly/Elan), tramiprosate (Neurochem) and AN1792 (Elan).